Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is defined by the degeneration of nigral dopaminergic (DA) neurons and can be caused by monogenic mutations of genes such as parkin. The lack of phenotype in parkin knockout mice suggests that human nigral DA neurons have unique vulnerabilities. Here we generate induced pluripotent stem cells from normal subjects and PD patients with parkin mutations. We demonstrate that loss of parkin in human midbrain DA neurons greatly increases the transcription of monoamine oxidases and oxidative stress, significantly reduces DA uptake and increases spontaneous DA release. Lentiviral expression of parkin, but not its PD-linked mutant, rescues these phenotypes. The results suggest that parkin controls dopamine utilization in human midbrain DA neurons by enhancing the precision of DA neurotransmission and suppressing dopamine oxidation. Thus, the study provides novel targets and a physiologically relevant screening platform for disease-modifying therapies of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD patient iPSC-derived dopaminergic neurons harboring Parkin mutation displayed decreased microtubule stability, increased oxidative stress, reduced dopamine uptake, and increased spontaneous dopamine release [36,37].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“In sharp contrast to the situation seen in PD patients with parkin mutation”
ResultParkin is recruited selectively to impaired mitochondria and promotes their autophagy
Narendra, D., Tanaka, A., Suen, D.-F., & Youle, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200809125 · Cited by 4,026 · cited 1×
“Parkin mutations did not significantly affect mitochondria We examined whether the loss of parkin significantly affect mitochondria by treating the four lines of iPSC-derived neurons without or with CCCP (10 μM for 16 h) to induce mitophag”
BackgroundHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
MONOAMINE OXIDASE: From Genes to Behavior
Shih, J. C., Chen, K., & Ridd, M. J. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.197 · Cited by 1,206 · cited 1×
“, which are mitochondrial enzymes responsible for the oxidative deamination of dopamine , a reaction that produces large quantities of reactive oxygen specie”
BackgroundHu, B.-Y., Weick, J. P., Yu, J., Ma, L.-X., Zhang, X.-Q., Thomson, J. A., & Zhang, S.-C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910012107 · Cited by 1,013
Oxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971
Research works printed but not linked: 1
- Chambers SM Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling Nat Biotechnol 27 275 280 2009 19252484 PMC2756723
Cited by
Items 101–200 of 252
Vecchia, E. D., Mortimer, N., Palladino, V. S., Kittel‐Schneider, S., Lesch, K., Reif, A., Schenck, A., & Norton, W. (2018) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000211 · Cited by 41
“The creation of human midbrain DA neurons from these stem cells uncovered an increase of DA release from terminals accompanied by decreased DAT expression and lower reuptake (Jiang et al., 2012).”
BackgroundAli, M. Z., & Dholaniya, P. S. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105344 · Cited by 34
Modeling Parkinson’s Disease Using Induced Pluripotent Stem Cells
Hu, X., Mao, C., Fan, L., Luo, H., Hu, Z., Zhang, S., Yang, Z., Zheng, H., Sun, H., Fan, Y., et al. (2020) · Stem Cells International · doi:10.1155/2020/1061470 · Cited by 42
“So, parkin was presumed to control dopamine utilization in human mDA neurons by increasing the accuracy of dopamine neurotransmission and inhibiting dopamine oxidation [98].”
BackgroundSmith, D. K., He, M., Zhang, C., & Zheng, J. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.006 · Cited by 36
“Parkinson disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”
BackgroundInfluentialRecent advances of induced pluripotent stem cells application in neurodegenerative diseases
Amin, N., Tan, X., Ren, Q., Zhu, N., Botchway, B. O. A., Hu, Z., & Fang, M. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109674 · Cited by 39
Centimetre-scale fullerene-free tin-based perovskite solar cells with a 14.51% certified efficiency
Li, T., He, F., Shen, T., Yan, D., Jin, Z., Li, B., Wang, P., Zhang, Z., Li, Z., Pu, Y., et al. (2025) · Nature Energy · doi:10.1038/s41560-025-01919-1 · Cited by 31
Li, Z., Cao, P., Meng, H., Li, D., Zhang, Y., Li, Y., & Wang, S. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.125230 · Cited by 32
Guided Self‐Propelled Leaping of Droplets on a Micro‐Anisotropic Superhydrophobic Surface
Liu, J., Guo, H., Zhang, B., Qiao, S., Shao, M., Zhang, X., Feng, X., Li, Q., Song, Y., Jiang, L., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201600224 · Cited by 31
Generation of human A9 dopaminergic pacemakers from induced pluripotent stem cells
Li, H., Jiang, H., Li, H., Li, L., Yan, Z., & Feng, J. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01628-1 · Cited by 35
“The C001, C002 [36] and C005 [37] human iPSCs (at passages 25–45) were generated and cultured as described previously.”
BackgroundMethodInfluentialInduced dopaminergic neurons: A new promise for Parkinson’s disease
Xu, Z., Chu, X., Jiang, H., Schilling, H. A., Chen, S., & Feng, J. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.009 · Cited by 32
“While iPSCs provide a permanent and replenishable resource to generate patient-specific midbrain DA neurons, their drawbacks are the long time required to differentiate iPSCs to mature midbrain DA neurons [97] and the resetting of epigenetic information during reprogramming [98].”
BackgroundInduced pluripotent stem cell‐based modeling of mutant LRRK 2‐associated Parkinson's disease
Weykopf, B., Haupt, S., Jungverdorben, J., Flitsch, L. J., Hebisch, M., Liu, G., Suzuki, K., Belmonte, J. C. I., Peitz, M., Blaess, S., et al. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14345 · Cited by 32
“Importantly, accumulation of α‐syn does not represent a LRRK2‐specific pathophenotype as similar data have been generated for various different models of familial PD, including iPSC models for triplication of the SNCA gene (SNCAtrp) (Byers et al., 2011; Flierl et al., 2014; Mazzulli, Zunke, Isacson, Studer, & Krainc,…”
BackgroundInfluentialNeuronal microtubules and proteins linked to Parkinson’s disease: a relevant interaction?
Calogero, A. M., Mazzetti, S., Pezzoli, G., & Cappelletti, G. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0142 · Cited by 32
Qin, H., Zhao, A., Sun, M., Ma, K., & Fu, X. (2020) · Military Medical Research · doi:10.1186/s40779-020-00284-2 · Cited by 37
Dopamine Induces Oscillatory Activities in Human Midbrain Neurons with Parkin Mutations
Zhong, P., Hu, Z., Jiang, H., Yan, Z., & Feng, J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.023 · Cited by 29
“In contrast, P002 neurons transduced with lentivirus expressing the PD-causing T240R mutant parkin (Jiang et al., 2012) exhibited strong rhythmic bursting of sEPSCs (Figures 7A, 7B, (A and B) Normalized plots of sEPSC amplitude (A) and frequency (B), showing the effect of dopamine (100 mM) in the…”
BackgroundMethodResultInfluentialDisease modelling using human iPSCs
Chamberlain, S. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw209 · Cited by 32
Using induced pluripotent stem cells for modeling Parkinson’s disease
Ke, M., Chong, C., & Su, H. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i9.634 · Cited by 32
Kouroupi, G., Antoniou, N., Prodromidou, K., Taoufik, E., & Matsas, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197113 · Cited by 32
“Oxidative stress: increased ROS and carbonylated proteins; upregulation of proteins involved in dopamine oxidation Triplication [41,43,46] G2019S [62] I2020T [63] Ex2–4 del & Ex6–7 del [49] Ex3, 5, and 6 del [50] Ex3 del/Ex5 del and Ex3 del/Ex 3 del [64] Q456X [60,65]”
BackgroundLi, H., Jiang, H., Yin, X., Bard, J., Zhang, B., & Feng, J. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.089 · Cited by 29
“Lentivirus production was performed as described previously [19].”
Method1D Photonic Topological Insulators Composed of Split Ring Resonators: A Mini Review
Guo, Z., Wang, Y., Ke, S., Su, X., Ren, J., & Chen, H. (2023) · Advanced Physics Research · doi:10.1002/apxr.202300125 · Cited by 36
Stem cells and the treatment of Parkinson's disease
Ali, F. R., Stott, S., & Barker, R. A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.017 · Cited by 29
“In this study the authors demonstrated Please cite this article as: Ali, F., et al., Stem cells and the treatment of j.expneurol.2012.12.017 that the patient iPSCs-derivedmidbrain DA neurons showed altered dopaminergic neurotransmission (Jiang et al., 2012).”
InfluentialThe Use of Induced Pluripotent Stem Cell Technology to Advance Autism Research and Treatment
Acab, A., & Muotri, A. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0354-x · Cited by 33
Induced Pluripotent Stem Cells to Model and Treat Neurogenetic Disorders
Wang, H., & Doering, L. C. (2012) · Neural Plasticity · doi:10.1155/2012/346053 · Cited by 32
“[174] demonstrated that in DA neurons from iPSCs of PD patients with parkin mutations, the transcription of monoamine oxidases and oxidative stress are greatly increased, DA uptake is reduced, and spontaneous DA release is increased.”
BackgroundHu, Z., Pu, J., Jiang, H., Zhong, P., Qiu, J., Li, F., Wang, X., Zhang, B., Yan, Z., & Feng, J. (2015) · Stem Cells and Development · doi:10.1089/scd.2015.0079 · Cited by 25
“In our previous study, we have generated induced pluripotent stem cells (iPSCs) from PD patients with parkin mutations and found that parkin mutations disrupt the precision of DA neurotransmission by increasing spontaneous release of dopamine and decreasing selective uptake of dopamine [10].”
BackgroundMethodInfluentialMomčilović, O., Sivapatham, R., Oron, T. R., Meyer, M., Mooney, S. D., Rao, M. S., & Zeng, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154890 · Cited by 25
Iwasawa, C., Kuzumaki, N., Suda, Y., Kagawa, R., Oka, Y., Hattori, N., Okano, H., & Narita, M. (2019) · Molecular Brain · doi:10.1186/s13041-019-0426-7 · Cited by 30
Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells
LaMarca, E. A., Powell, S. K., Akbarian, S., & Brennand, K. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00082 · Cited by 30
“Generation of hiPSC-derived midbrain DA neurons from patients with Parkin mutations revealed an increased oxidative stress and a spontaneous dopamine release mediated by increased transcription of monoamine oxidases (138).”
BackgroundXie, Y., & Zhang, R. X. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1989-9 · Cited by 28
“PARK2 Fibroblasts Dopaminergic neurons Yes Lentiviral expression of Parkin [21, 22]”
BackgroundInfluentialUtilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification
Pu, J., Frescas, D., Zhang, B., & Feng, J. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215584932 · Cited by 26
“To that end, iPSCs derived from the somatic cells of patients can provide a useful tool for studying the underlying mechanism of human disease and may serve as a promising source for cell replacement therapies.(70,71) Due to the unpredictable genetic variations of patientderived iPSCs, researchers have been challenged…”
BackgroundThe Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease
Kang, J.-F., Tang, B., & Guo, J. (2016) · Stem Cells International · doi:10.1155/2016/4126214 · Cited by 24
“There was also an increased level of reactive oxygen species (ROS) in these neurons as a result of mitochondrial dysfunction, which indicates that Parkin can enhance the precision of DA neurotransmission and suppress the oxidation of DA [35, 36].”
Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC‐Based Models
Fernández‐Santiago, R., & Ezquerra, M. (2015) · Stem Cells International · doi:10.1155/2016/9464591 · Cited by 24
“[23] H.”
Liu, T., Zhang, H., Zheng, J., Lin, J., Huang, Y., Chen, J., Yu, Z., Guo, L., Pan, W., Xiong, Y., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13512 · Cited by 22
“The cells were maintained in culture for 5 weeks [13, 14].”
BackgroundType A monoamine oxidase; its unique role in mood, behavior and neurodegeneration
Naoi, M., Maruyama, W., Shamoto‐Nagai, M., & Riederer, P. F. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02866-z · Cited by 28
“Loss of parkin increased MAO-A and MAO-B expression in induced pluripotent stem cells (iPSC)- derived neurons from patients with parkin mutation (Jiang et al. 2012).”
Mohamed, N., Larroquette, F., Beitel, L. K., Fon, E. A., & Durcan, T. M. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-181515 · Cited by 26
The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease
Burbulla, L. F., & Krainc, D. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104545 · Cited by 23
Zhao, H., Xie, J., Wu, S., Zhao, X., Sánchez, O. F., Min, S.-H., Rochet, J., Freeman, J. L., & Yuan, C. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.168307 · Cited by 22
Interplay between α-synuclein and parkin genes: Insights of Parkinson’s disease
Sharma, K., Chib, S., Gupta, A., Singh, R., & Chalotra, R. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09520-7 · Cited by 23
“These studies revealed increased dopamine release in autosomal recessive juvenile parkinsonism, indicating that loss of Parkin function leads to enhanced dopamine release [45].”
Redefining Parkinson’s Disease Research Using Induced Pluripotent Stem Cells
Pu, J., Jiang, H., Zhang, B., & Feng, J. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0288-1 · Cited by 24
Cellular reprogramming: a new approach to modelling Parkinson's disease
Hartfield, E. M., Fernandes, H. J. R., Vowles, J., Cowley, S. A., & Wade‐Martins, R. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120159 · Cited by 26
Li, S., Liu, Y., Lu, S., Xu, J., Liu, X., Yang, D., Yang, Y., Hou, L., & Li, N. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04985-3 · Cited by 25
“In iPSC-derived DA neurons from LRRK2 I2020T, PARKIN mutation, and OPA1 mutation patients, an increase in carbonylated proteins was observed, which reflected protein oxidation [96, 97, 98].”
Deflorio, C., Blanchard, S., Carisi, M. C., Bohl, D., & Maskos, U. (2016) · The FASEB Journal · doi:10.1096/fj.201600932r · Cited by 23
Paik, E. J., O’Neil, A., Ng, S., Sun, C., & Rubin, L. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-19291-4 · Cited by 21
Naoi, M., Maruyama, W., Shamoto‐Nagai, M., & Riederer, P. F. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-023-02730-6 · Cited by 24
“MAO-A and MAO-B expression increased in iPSC-derived neurons from patients with parkin mutation (Jiang et al. 2012).”
Hennis, M. R., Seamans, K. W., Marvin, M. A., Casey, B. H., & Goldberg, M. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084894 · Cited by 26
“Consistent with this possibility, Parkin and DJ-1 have been found in cell membranes and vesicles [95,96] and mutations in Parkin and DJ-1 can cause altered dopamine release, reuptake and signaling [20,97,98].”
BackgroundInfluence of surface roughness on neural differentiation of human induced pluripotent stem cells
Li, Z., Wang, W., Kratz, K. L., Küchler, J., Xu, X., Zou, J., Deng, Z., Sun, X., Gossen, M., Ma, N., et al. (2016) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-168121 · Cited by 25
“For example, the dopaminergic neurons as the predominant cell type for treating PD have been effectively generated from iPSCs [17, 30], and functionally integrated into cynomolgus monkey model [14].”
Parkinson’s disease: what the model systems have taught us so far
Ghatak, S., Trudler, D., Dolatabadi, N., & Ambasudhan, R. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0960-6 · Cited by 23
Induced Pluripotent Stem Cells and Their Use in Cardiac and Neural Regenerative Medicine
Skalová, Š., Švadláková, T., Qureshi, W. M. S., Dev, K., & Mokrý, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16024043 · Cited by 21
“It also led to elevated oxidative stress induced by dopamine oxidation [125].”
BackgroundCell replacement therapy is the remedial solution for treating Parkinson’s disease
Dhivya, V., & Vellingiri, B. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.06.08 · Cited by 19
Yokota, M., Kakuta, S., Shiga, T., Ishikawa, K., Okano, H., Hattori, N., Akamatsu, W., & Koike, M. (2021) · Molecular Brain · doi:10.1186/s13041-021-00771-0 · Cited by 26
“In contrast, in patientspecific induced pluripotent stem cell (iPSC)-derived neurons, PRKN mutations have been reported to result in abnormal mitochondrial morphology and a failure of mitochondrial degradation [12–14], an inability to form complex neuronal morphology [15], and reduced dopamine use [16].”
BackgroundAntonov, S. A., & Novosadova, E. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073381 · Cited by 24
Tan, K. K. B., Lim, W. W. M., Chai, C., Kukumberg, M., Lim, K., Goh, E. L. K., & Yim, E. K. F. (2018) · Scientific Reports · doi:10.1038/s41598-018-27653-1 · Cited by 22
Jacobs, B. M. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-130268 · Cited by 20
“In contrast, another group found that PARK2-mutant neurons showed no signs of increased basal oxidative stress, which they measured indirectly by quantifying the protein carbonyl content of the neurons [16].”
BackgroundBaden, P., Yu, C., & Deleidi, M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.023 · Cited by 17
Lin, L., Liu, A., Li, H., Feng, J., & Yan, Z. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190190 · Cited by 18
Induced pluripotent stem cells and Parkinson's disease: modelling and treatment
Xu, X., Huang, J., Li, J., Liu, L., Han, C., Shen, Y., Zhang, G., Jiang, H., Lin, Z., Xiong, N., et al. (2016) · Cell Proliferation · doi:10.1111/cpr.12229 · Cited by 21
Lopes, C., & Rego, A. C. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9714-8 · Cited by 18
Functional Evaluations of Genes Disrupted in Patients with Tourette’s Disorder
Sun, N., Tischfield, J. A., King, R. A., & Heiman, G. A. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00011 · Cited by 17
Ochałek, A., Szczęsna, K., Petazzi, P., Kobolák, J., & Dinnyés, A. (2016) · Stem Cells International · doi:10.1155/2016/5838934 · Cited by 18
“It suggests that PARK2 controls dopamine neurotransmission and suppresses dopamine oxidation [58].”
Solving the puzzle of Parkinson’s disease using induced pluripotent stem cells
Zhao, P., Luo, Z., Tian, W., Yang, J., Ibañez, D. P., Huang, Z., Tortorella, M. D., Esteban, M. A., & Fan, W. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214538588 · Cited by 21
“For example, Jiang et al.(34) observed that dopamine-induced oxidative stress in DA neurons is regulated by Parkin through the enzyme monoamine oxidase.”
BackgroundKim, J. J., Daadi, E. W., Oh, T. T., Daadi, E. S., & Daadi, M. M. (2022) · Genes · doi:10.3390/genes13111937 · Cited by 14
Central nervous system organoids for modeling neurodegenerative diseases
Hou, P., & Kuo, H. (2022) · IUBMB Life · doi:10.1002/iub.2595 · Cited by 14
Discovery of new epigenomics-based biomarkers and the early diagnosis of neurodegenerative diseases
Lee, D., Choi, Y. H., Seo, J., Kim, J. K., & Lee, S. B. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101069 · Cited by 14
Lebedeva, O. S., Sharova, E. I., Grekhnev, D. A., Skorodumova, L., Kopylova, I. V., Vassina, E. M., Oshkolova, A., Novikova, I. V., Krisanova, A. V., Olekhnovich, E. I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087297 · Cited by 13
“Parkin controls dopamine utilization in DAns of the midbrain by increasing the accuracy of dopaminergic transmission and suppressing dopamine oxidation [78].”
BackgroundResultGeneration of human midbrain organoids from induced pluripotent stem cells
Mohamed, N., Mathur, M., da Silva, R. V., Thomas, R. A., Lépine, P., Beitel, L. K., Fon, E. A., & Durcan, T. M. (2019) · MNI Open Research · doi:10.12688/mniopenres.12816.1 · Cited by 28
Jia, C., Cheng, C., Li, T., Chen, X., Yang, Y., Liu, X., Li, S., & Le, W. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.653379 · Cited by 14
“Moreover, both MAOA and MAOB transcription levels and enzymatic activities are significantly increased in the induced pluripotent stem cells of dermal fibroblasts from PD patients with parkin mutations (Jiang et al., 2012).”
BackgroundConnectivity and circuitry in a dish versus in a brain
Chinchalongporn, V., Koppensteiner, P., Prè, D., Thangnipon, W., Bilo, L., & Arancio, O. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0129-y · Cited by 15
Diverse Functions of Parkin in Midbrain Dopaminergic Neurons
Song, P., & Krainc, D. (2024) · Movement Disorders · doi:10.1002/mds.29890 · Cited by 13
“41,42 These different conclusions might be because of the different patient lines, examination methods, protocols for differentiation, 43 and stages of the dopaminergic neurons ’ maturity.”
iPS models of Parkin and PINK1
Raković, A., Seibler, P., & Klein, C. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150010 · Cited by 14
Nucleolar Molecular Signature of Pluripotent Stem Cells
Pliss, A., Kuzmin, A. N., Kachynski, A. V., Jiang, H., Hu, Z., Ren, Y., Feng, J., & Prasad, P. N. (2013) · Analytical Chemistry · doi:10.1021/ac303806j · Cited by 12
Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons
Ren, Y., Jiang, H., Pu, J., Li, L., Wu, J., Yan, Y., Zhao, G., Guttuso, T. J., Zhang, B., & Feng, J. (2021) · Movement Disorders · doi:10.1002/mds.28786 · Cited by 12
“Measurements of dopamine release and uptake were performed as described previously.(6)”
MethodInfluentialCurrent Development of iPSC-Based Modeling in Neurodegenerative Diseases
Guo, X., Wang, X., Wang, J., Ma, M., & Ren, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083774 · Cited by 17
“DA neurons derived from PARK2 and PINK1 iPSCs exhibit typical PD-like pathological features, including α -synuclein accumulation, defects in mitochondrial autophagy, elevated ROS levels, and increased sensitivity to oxidative stress [182–185].”
Mishima, T., Fujioka, S., Fukae, J., Yuasa‐Kawada, J., & Tsuboi, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123870 · Cited by 13
“In PRKN mutation-carrying iPSC-derived DA neurons, increased oxidative stress levels and the abnormality of dopamine release and uptake were detected and Parkin expression rescued such phenotypes [41,42].”
BackgroundSaleem, K., Xiao, Z., Zhu, B., Ren, Y., Yan, Z., & Feng, J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03225-4 · Cited by 10
“Total RNA was extracted from iPSC-derived neuronal cultures at D40 using TRIzol (ThermoFisher) and cleaned with an RNeasy kit (QIAGEN).”
The occurrence and development of induced pluripotent stem cells
Chen, Y., Li, M., & Wu, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1389558 · Cited by 18
Parkin regulates drug-taking behavior in rat model of methamphetamine use disorder
SHARMA, A. K., Harutyunyan, A., Schneider, B. L., & Moszczyńska, A. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01387-7 · Cited by 9
Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
Sánchez‐Danés, A., Benzoni, P., Memo, M., Dell`Era, P., Raya, Á., & Consiglio, A. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152731131200128 · Cited by 12
Li, H., Hu, Z., Jiang, H., Pu, J., Selli, I., Qiu, J., Zhang, B., & Feng, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67143-x · Cited by 10
Li, B., Jiang, H., Li, H., Zhang, B., Slaughter, M. M., Yan, Z., & Feng, J. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220963755 · Cited by 11
“Collection of lentivirus and infection of hRPE cells were conducted as described previously.(17) HEK293FT cells (Invitrogen) were cultured at 4–6 10(6) cells in a 10 cm cell culture dish.”
MethodLanglie, J. A., Mittal, R., Finberg, A., Bencie, N. B., Mittal, J., Omidian, H., Omidi, Y., & Eshraghi, A. A. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335836 · Cited by 10
“These models have shown that dopaminergic neurons in PD are adversely affected and susceptible to oxidative stress with LRRK2 mutations (Jiang et al., 2012).”
BackgroundHuman Stem Cells for Craniomaxillofacial Reconstruction
Jalali, M., Kirkpatrick, W. N. A., Cameron, M. G., Pauklin, S., & Vallier, L. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0576 · Cited by 11
Modelling neurodegenerative diseases in vitro: Recent advances in 3D iPSC technologies
Siney, E. J., Kurbatskaya, K., Chatterjee, S., Prasannan, P., Mudher, A. K., & Willaime‐Morawek, S. (2018) · AIMS Cell and Tissue Engineering · doi:10.3934/celltissue.2018.1.1 · Cited by 11
“VMAT2+, AADC+, spontaneous APs, EPSC, voltage gated Na+& K+ currents and NMDA and GABA gated currents [118]”
BackgroundState of the Art in Sub-Phenotyping Midbrain Dopamine Neurons
Basso, V., Döbrössy, M. D., Thompson, L. H., Kirik, D., Fuller, H. R., & Gates, M. A. (2024) · Biology · doi:10.3390/biology13090690 · Cited by 12
A compendious summary of Parkinson’s disease patient-derived iPSCs in the first decade
Ren, C., Wang, F., Guan, L.-N., Cheng, X.-Y., Zhang, C.-Y., Geng, D., & Liu, C. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.16 · Cited by 9
Presynaptic Dysfunction by Familial Factors in Parkinson Disease
Lee, W., Koh, S., Hwang, S., & Kim, S. H. (2018) · International Neurourology Journal · doi:10.5213/inj.1836216.108 · Cited by 8
“Dopaminergic neurons derived from patient-based human-induced pluripotent stem cell exhibit that spontaneous release of dopamine is also increased [44], implying that the patient has somehow dominant negative parkin form.”
BackgroundDrouin‐Ouellet, J., & Barker, R. (2012) · Stem Cells International · doi:10.1155/2012/926147 · Cited by 9
“Parkin mutation Increased transcription of monoamine oxidases and oxidative stress, reduced DA uptake and increased spontaneous DA release [20]”
BackgroundRadtke, F., Palladino, V. S., McNeill, R. V., Chiocchetti, A. G., Haslinger, D., Leyh, M., Gersic, D., Frank, M., Grünewald, L., Klebe, S., et al. (2022) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32918 · Cited by 9
“HiPSC derived dopaminergic neurons from PD patients carrying a CNV deletion in PARK2 showed an increased dopamine release with lower reuptake of this neurotransmitter (Jiang et al., 2012).”
BackgroundStem Cell-Based Approaches in Parkinson's Disease Research
Kim, M. S., Yoon, S., Choi, J., Kim, Y. J., & Lee, G. (2024) · International Journal of Stem Cells · doi:10.15283/ijsc23169 · Cited by 9
Jung‐Klawitter, S., & Opladen, T. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0225-9 · Cited by 9
Stem cell reprogramming: Basic implications and future perspective for movement disorders
Brändl, B., Schneider, S. A., Loring, J. F., Hardy, J., Gribbon, P. M., & Müller, F. (2014) · Movement Disorders · doi:10.1002/mds.26113 · Cited by 9
Dopaminergic differentiation using pluripotent stem cells
Momčilović, O., Montoya‐Sack, J., & Zeng, X. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24251 · Cited by 9
“, 2011], PARK2 mutations [Jiang et al., 2012], as well as from patients with sporadic PD [Soldner et al.”
BackgroundChristian, K. M., Song, H., & Ming, G.-L. (2012) · Frontiers in Biology · doi:10.1007/s11515-012-1216-0 · Cited by 6
“…spontaneous dopamine release; enhanced transcription of MAO-A, MAO-B; increased oxidative stress Overexpression of WT-parkin rescued all phenotypes Jiang et al., 2012 PD α synuclein point mutation Dopaminergic neurons ~ ZFN gene-editing; repair of point mutation in patient iPSCs; introduction of…”
Identification of DOT1L inhibitor in a screen for factors that promote dopaminergic neuron survival
Cui, J., Carey, J., & Pera, R. A. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1026468 · Cited by 6
Pu, J., Lin, L., Jiang, H., Hu, Z., Li, H., Yan, Z., Zhang, B., & Feng, J. (2023) · Movement Disorders · doi:10.1002/mds.29434 · Cited by 6
iPSCs-Derived Neurons and Brain Organoids from Patients
Zhu, W., Xu, L., Li, X., Hu, H., Lou, S.-N., & Liu, Y. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_657 · Cited by 5
Carr, L. M., Mustafa, S., Care, A., & Collins‐Praino, L. E. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.04.023 · Cited by 6
“…dopaminergic neurons that express pathological PD mutations and show PD-like pathology in culture, including increased pathological α -synuclein aggregates (Kouroupi et al., 2017), neurite degeneration (S ´ anchez-Dan ´ es et al., 2012) and dysregulated dopamine pathways (Jiang et al., 2012).”
BackgroundUsing Induced Pluripotent Stem Cells to Model Neurodegenerative Diseases
Gu, H. (2013) · Journal of Ancient Diseases & Preventive Remedies · doi:10.4172/2329-8731.1000e101 · Cited by 5
“This paper verified the specific function of parkin in midbrain dopaminergic neurons [10].”
BackgroundMultipotent stem cells with neural crest stem cells characteristics exist in bovine adipose tissue
Zhang, K., Cui, X., Zhang, B., Song, X., Liu, Q., & Yang, S. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.176 · Cited by 6
“OCT4, SOX2, and KLF4 have been regarded as the typical endogenous pluripotent genes in human iPS stem cells[29].”
BackgroundLinking Heat Shock Protein 70 and Parkin in Parkinson’s Disease
Zhao, Z., Li, Z., Du, F., Wang, Y., Wu, Y., Lim, K., Li, L., Yang, N., Yu, C., & Zhang, C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03481-x · Cited by 5
“One study reported that Parkin activated protein phosphatase 2A (PP2A) and inhibited Polo-like kinase 2 (PLK2) to reduce p-a-synuclein levels and inhibit the formation of toxic oligomers, ultimately preventing protein aggregation [77, 78].”
BackgroundStem Cell Technology for (Epi)genetic Brain Disorders
Riemens, R. J. M., Soares, E. S., Esteller, M., & Delgado‐Morales, R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_23 · Cited by 8
Lebedeva, O. S., Poberezhniy, D., Novosadova, E. V., Gerasimova, T., Novosadova, L. V., Arsenyeva, E. L., Stepanenko, E. A., Shimchenko, D., Volovikov, E. A., Anufrieva, K. S., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03293-z · Cited by 4
“On the other hand, Parkin suppresses dopamine oxidation in human DA neurons in the midbrain [84] and increases dopamine uptake by enhancing the ubiquitination and degradation of the misfolded dopamine transporter.”
BackgroundKovalenko, V., Александровна, Х. Е., Рзаев, Д. А., & Medvedev, S. P. (2017) · Genes and Cells · doi:10.23868/201707012 · Cited by 4
Metadata
- Authors
- Jiang, H., Ren, Y., Yuen, E. Y., Zhong, P., Ghaedi, M., Hu, Z., Azabdaftari, G., Nakaso, K., Yan, Z., & Feng, J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Roswell Park Comprehensive Cancer Center (US)
- Tottori University (JP)
- Corresponding author
- Feng, Jian
- Venue
- Nature Communications
- Published
- 2012-02-07
- Volume
- 3
- Issue
- 1
- Pages
- 668-668
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3498452
- OpenAlex
- W2010478595
- Cited by
- 254
- References
- 39
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 12 · 2023: 10 · 2022: 19 · 2021: 20 · 2020: 16 · 2019: 26 · 2018: 24 · 2017: 16 · 2016: 24 · 2015: 17 · 2014: 18 · 2013: 24 · 2012: 15
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Communications (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Roswell Park Cancer Institute
- State University of New York
- New York State Stem Cell Science
- National Natural Science Foundation of China (30928006)
- National Institutes of Health (5rc2ns070276-02, NS070276)
- U.S. Public Health Service (C024406)
- National Institute of Mental Health (R25MH077823)
- National Institute on Drug Abuse (R01DA026947)
- National Institute of Neurological Disorders and Stroke (RC2-NS070276, NS061856, R01NS061856, NS071122, NS070276, R01NS071122)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkin, Parkinson's disease, dopaminergic neurons, midbrain, dopamine uptake, dopamine release, monoamine oxidase, oxidative stress, induced pluripotent stem cells, parkin mutations, ubiquitin ligase, disease-modifying therapy
- MeSH terms
- Animals, Binding Sites, Brain, Dopamine, Fibroblasts, Gene Expression Regulation, Humans, Mitochondria, Models, Biological, Monoamine Oxidase, Mutation, Neurons, Oxygen, Parkinson Disease, Phenotype, Skin, Time Factors, Oxidative Stress, Ubiquitin-Protein Ligases, Mice, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.